Wed, Apr 24, 2024
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Industry Updates

October Barclay Hedge Fund Index up 0.96% (+8.31% YTD)

Friday, November 10, 2017
Opalesque Industry Update - Hedge Funds extended their winning streak to 12 months with a 0.96% gain in October, according to the Barclay Hedge Fund Index compiled by BarclayHedge. The index is up 8.31% for the year and has gained 10.40% since the current winning streak began in November 2016.

"Strong global equity markets continued to fuel broad based hedge fund gains," says Sol Waksman, founder and president of BarclayHedge. Fourteen of Barclay's 17 hedge fund indices registered positive returns for the month.

"Driven by positive earnings reports, the S&P 500 and NASDAQ both ended the month at new all-time highs. Shinzo Abe's re-election as Japan's Prime Minister propelled the Nikkei 225 to its highest level in 20 years."

Technology extends gains

Technology has been the big gainer year to date with a rise of 21.09% and led all indices last month with a gain of 2.83%. Pacific Rim Equities (2.41%), Equity Long Bias (1.76%) and Global Macro (1.63%) also were strong in October.

Healthcare and Biotechnology, which is the second best performing sector for the year at 15.23%, registered the biggest slide (-1.69) in October. Event Driven (-0.92%) and Distressed Securities (-1.14%) also posted losses for the month.

"Healthcare and Biotechnology has been strong in 2017 but suffered last month as Congress failed in their efforts to 'repeal and replace' the Affordable Care Act (Obamacare)." according to Waksman. "Pharmaceutical stocks were particularly affected and were a big contributor to the losses."

In other year to date returns, Emerging Markets follows Technology and Healthcare & Biotechnology with a rise of 14.60% so far in 2017. All of Barclay's 17 hedge fund indices are profitable through month-end October. The sectors with the smallest gains for the year have been Convertible Arbitrage (3.06%), Equity Market Neutral (2.89%), and Distressed Securities (0.58%).

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1